Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
    1.
    发明公开
    Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia 审中-公开
    用于降低胆固醇水平,而不Hypertriglyderidämie造成化合物和方法

    公开(公告)号:EP1972635A1

    公开(公告)日:2008-09-24

    申请号:EP08003372.3

    申请日:2001-04-06

    IPC分类号: C07H21/04 C07K14/775

    摘要: This invention provides methods of lowering cholesterol, delaying the onset of atherosclerosis, or treating atherosclerosis in a mammal without inducing hypertriglyceridemia. These methods involve administering to or expressing in a mammal, an apoE polypeptide or nucleic acid that, when administered to or expressed in a mammal, lowers the total serum cholesterol level without inducing hypertriglyceridemia.

    摘要翻译: 本发明提供了降低胆固醇,动脉粥样硬化延缓其发作或不诱导高甘油三酯血症治疗哺乳动物中的动脉粥样硬化的方法。 这些方法包括给予或哺乳动物中表达,载脂蛋白E的多肽或核酸,当给予或过表达在哺乳动物中,降低而不诱导高甘油三酯血症的总血清胆固醇水平的。

    Pharmaceutical combination
    3.
    发明公开
    Pharmaceutical combination 失效
    Pharmazeutische组合

    公开(公告)号:EP1743630A2

    公开(公告)日:2007-01-17

    申请号:EP06017607.0

    申请日:1998-07-31

    IPC分类号: A61K9/22 A61K31/44 A61K31/60

    摘要: There is disclosed a pharmaceutical combination for lessening or preventing any flush reaction caused by nicotinic acid therapy, the combination comprising nicotinic acid and a nonsteroidal anti-inflammatory drug in an amount effective to inhibit or reduce prostaglandin D 2 (PGD 2 ) synthesis.

    摘要翻译: 公开了用于减轻或防止由烟酸治疗引起的任何冲洗反应的药物组合,该组合包含有效抑制或降低前列腺素D 2(PGD 2)合成的量的烟酸和非甾体抗炎药。

    ALLEVIATING OR PREVENTION OF MIGRAINE HEADACHE ONSET WITH MAST CELL DEGRANULATION BLOCKING AGENTS
    6.
    发明公开
    ALLEVIATING OR PREVENTION OF MIGRAINE HEADACHE ONSET WITH MAST CELL DEGRANULATION BLOCKING AGENTS 失效
    用细胞降解阻断剂缓解或预防偏头痛发作

    公开(公告)号:EP0618796A1

    公开(公告)日:1994-10-12

    申请号:EP93902768.0

    申请日:1992-12-28

    IPC分类号: A61K31

    摘要: Méthode permettant de prévenir ou de soulager la migraine consistant à administrer une dose pharmaceutiquement efficace d'une substance bloquant la dégranulation des mastocytes juste avant ou pendant la phase prodromique de la migraine en l'absence d'un analgésique. La substance peut également être administrée en même temps qu'un stimulant du système nerveux central.

    摘要翻译: 一种预防或缓解偏头痛的方法,通过在不存在镇痛剂的情况下在偏头痛的前驱阶段之前或期间施用药学有效剂量的阻断肥大细胞脱粒的物质。 该物质也可以与中枢神经系统的兴奋剂一起施用。

    BREATH COORDINATED INHALER
    7.
    发明授权
    BREATH COORDINATED INHALER 失效
    呼吸协调吸入器

    公开(公告)号:EP1007119B1

    公开(公告)日:2003-12-10

    申请号:EP98914481.1

    申请日:1998-04-03

    IPC分类号: A61M11/00 A61M15/00

    摘要: An improved breath coordinated inhaler (10) is provided for administering medication to a patient in aerosol form for respiratory inhalation therapy. The improved inhaler (10) comprises a compact housing (18) adapted to receive and support a medication canister (12), including a valve assembly (14) actuated to deliver a dosage of the medication in aerosol form. The housing (18) includes a plunger mounted at a first end thereof for displacing the canister against a spray nozzle (24) located at a second end of the housing to actuate the valve assembly (14), and deliver the medication through a mouthpiece (26) to the patient. The plunger (36) is associated with a seal arrangement for venting the housing (18) when the plunger is depressed to allow the patient to draw in air in timed relation to the medication delivery, and to substantially reseal the housing (18) against ingress of contaminants when the plunger (36) is released.

    摘要翻译: 提供改进的呼吸协调式吸入器(10),用于以气雾剂形式向患者施用用于呼吸吸入治疗的药物。 改进的吸入器(10)包括适于接收和支撑药物罐(12)的紧凑壳体(18),包括阀组件(14),所述阀组件被致动以递送一定剂量的气雾剂形式的药物。 壳体(18)包括安装在其第一端的柱塞,用于抵靠位于壳体的第二端处的喷嘴(24)移动罐以致动阀组件(14),并且将药物递送通过咬嘴 26)给患者。 柱塞(36)与用于在柱塞被压下时使壳体(18)排气以允许患者相对于药物输送定时吸入空气并且基本上重新密封壳体(18)以防止进入 当柱塞(36)被释放时污染物的量。

    BREATH COORDINATED INHALER
    9.
    发明公开
    BREATH COORDINATED INHALER 失效
    气雾

    公开(公告)号:EP1007119A1

    公开(公告)日:2000-06-14

    申请号:EP98914481.1

    申请日:1998-04-03

    IPC分类号: A61M11/00

    摘要: An improved breath coordinated inhaler (10) is provided for administering medication to a patient in aerosol form for respiratory inhalation therapy. The improved inhaler (10) comprises a compact housing (18) adapted to receive and support a medication canister (12), including a valve assembly (14) actuated to deliver a dosage of the medication in aerosol form. The housing (18) includes a plunger mounted at a first end thereof for displacing the canister against a spray nozzle (24) located at a second end of the housing to actuate the valve assembly (14), and deliver the medication through a mouthpiece (26) to the patient. The plunger (36) is associated with a seal arrangement for venting the housing (18) when the plunger is depressed to allow the patient to draw in air in timed relation to the medication delivery, and to substantially reseal the housing (18) against ingress of contaminants when the plunger (36) is released.

    摘要翻译: 提供改进的呼吸协调吸入器(10),用于以气溶胶形式向患者施用药物用于呼吸吸入治疗。 改进的吸入器(10)包括适于容纳和支撑药物罐(12)的紧凑的壳体(18),其包括被致动以递送药物剂量的气溶胶形式的阀组件(14)。 壳体(18)包括安装在其第一端处的柱塞,用于使罐抵靠位于壳体的第二端处的喷嘴(24)移动以致动阀组件(14),并且通过接口管 26)给病人 当柱塞被压下时,柱塞(36)与用于排出壳体(18)的密封装置相关联,以允许患者以与药物输送成时关系的方式抽吸空气,并且基本上重新密封壳体(18)以防止入口 当柱塞(36)被释放时的污染物。

    Nicotinic acid compositions for treating hyperlipidemia
    10.
    发明公开
    Nicotinic acid compositions for treating hyperlipidemia 失效
    Nicotinsäureenthaltende Zusammensetzungen zur Behandlung derHyperlipidämie。

    公开(公告)号:EP0643965A1

    公开(公告)日:1995-03-22

    申请号:EP94306847.8

    申请日:1994-09-19

    发明人: Bova, David J.

    IPC分类号: A61K31/445

    摘要: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic substantially immediately prior to each periodic physiological loss of consciousness.

    摘要翻译: 根据本发明的口服给药的抗高脂血症组合物包含约250至约3000重量份的烟酸和约5至约50重量份的羟丙基甲基纤维素。 而且,具有基本上周期性意识生理丧失的高脂血症的治疗高脂血症的方法包括以下步骤:形成具有有效的抗高脂血症量的烟酸的组合物和缓释剂的释放持续量。 该方法还包括在每次周期性意识生理丧失之前基本上立即将该组合物口服给予高脂血症的步骤。